STRATEC Biomedical AG (SBSG)

Xetra


	Symbol		Exchange		Currency
	SBSG		Xetra		EUR	Delayed
	SBSd		BATS Europe		EUR	Delayed
	SBSG		TradeGate		EUR	Delayed
	SBSG		Frankfurt		EUR	Delayed

Currency in EUR

29.100

-0.200(-0.68%)

Closed18:35:06

Fair Value

Day's Range

28.100

29.500

52 wk Range

26.050

48.600

SBSG Income Statement

Featured here, the Income Statement (earnings report) for STRATEC Biomedical AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

214.16

250.1

287.34

274.63

261.91

Total Revenues Growth

+14.02%

+16.78%

+14.89%

-4.42%

-4.63%

Cost Of Revenues

163.26

181.11

199.62

195.14

197.07

Gross Profit

50.9

68.99

87.71

79.49

64.85

Gross Profit Growth

+5.53%

+35.54%

+27.14%

-9.37%

-18.42%

Gross Profit Margin %

23.77%

27.58%

30.53%

28.94%

24.76%

Other Operating Expenses, Total

32.76

34.96

37.3

36.33

39.14

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+0.34%	+6.71%	+6.68%	-2.59%	+7.71%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	8.25	7.67	9.28	6.87	8.74
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	26.19	27.71	28.28	30.29	31.69
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-1.68	-0.42	-0.27	-0.83	-1.3

Operating Income

18.14

34.03

50.42

43.16

25.71

Operating Income Growth

+16.4%

+87.62%

+48.15%

-14.39%

-40.43%

EBIT Margin %

8.47%

13.61%

17.55%

15.72%

9.82%

Net Interest Expenses

-0.91

-1.08

-1.41

-1.8

-3.84

Net Interest Expenses Growth

-54.16%

-18.94%

-30.56%

-27.94%

-112.58%

Interest Expense, Total

-0.92

-1.08

-1.41

-1.86

-3.9

Interest And Investment Income

0.01

0

0

0.06

0.07

Other Non Operating Expenses, Total

-1

-0.34

-1.12

-1.56

-3

EBT, Excl. Unusual Items

16.23

32.61

47.89

39.8

18.87

Gain (Loss) On Sale Of Assets

0.01

-0

0.01

-0.44

-0.37

Other Unusual Items, Total

-

-

-1.05

-

-

EBT, Incl. Unusual Items

16.48

33.02

46.83

39.09

18.23

EBT, Incl. Unusual Items Growth

+16.98%

+100.35%

+41.82%

-16.54%

-53.36%

EBT, Incl. Unusual Items Margin

7.7%

13.2%

16.3%

14.23%

6.96%

Income Tax Expense

2.22

4.59

6.87

9.87

5.16

Net Income to Company

14.44

25.18

39.96

29.22

13.07

Minority Interest

-

-

-

-

-

Net Income

14.44

25.18

39.96

29.22

13.07

Net Income Growth

+61%

+74.34%

+58.72%

-26.87%

-55.29%

Net Income Margin %

6.74%

10.07%

13.91%

10.64%

4.99%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

14.26

28.44

39.96

29.22

13.07

Basic EPS - Continuing Operations

1.19

2.36

3.3

2.41

1.07

Basic EPS - Continuing Operations Growth

+27.82%

+98.22%

+39.95%

-26.99%

-55.37%

Diluted EPS - Continuing Operations

1.18

2.34

3.28

2.4

1.07

Diluted EPS - Continuing Operations Growth

+28.26%

+98.31%

+40.17%

-26.83%

-55.42%

Basic Weighted Average Shares Outstanding

11.99

12.06

12.11

12.13

12.16

Diluted Weighted Average Shares Outstanding

12.06

12.15

12.18

12.17

12.16

Dividend Per Share

0.84

0.9

0.95

0.97

0.55

Dividend Per Share Growth

+2.44%

+7.14%

+5.56%

+2.11%

-43.3%

EBITDA

33.44

48.89

63.11

54.68

37.3

EBITDA Growth

+6.03%

+46.22%

+29.08%

-13.36%

-31.78%

EBITDA Margin %

15.61%

19.55%

21.96%

19.91%

14.24%

EBIT